Trial Profile
A Phase 1, Randomised, Open-Label, Three-way Crossover Comparative Pharmacokinetic Study of Capsule and Tablet Dosage Forms of EMA401 Sodium Salt When Administered Orally in Healthy Adult Males
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Olodanrigan (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Pharmacokinetics
- Sponsors Spinifex Pharmaceuticals
- 02 Apr 2015 Status changed from not yet recruiting to completed as per Australian New Zealand Clinical Trial Registry.
- 03 Feb 2015 New trial record